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ABSTRACT
Small interfering RNAs (siRNAs) are short,
double-stranded RNAs that use the endogenous
RNAi pathway to mediate gene silencing.
Phosphorylation facilitates loading of a siRNA into
the Ago2 complex and subsequent cleavage of the
target mRNA. In this study, 20,3 0 seco nucleoside
modifications, which contain an acylic ribose ring
and are commonly called unlocked nucleic acids
(UNAs), were evaluated at all positions along the
guide strand of a siRNA targeting apolipopro-
tein B (ApoB). UNA modifications at positions 1, 2
and 3 were detrimental to siRNA activity. UNAs at
positions 1 and 2 prevented phosphorylation by Clp1
kinase, abrogated binding to Ago2, and impaired
Ago2-mediated cleavage of the mRNA target. The
addition of a 50-terminal phosphate to siRNA
containing a position 1 UNA restored ApoB mRNA
silencing, Ago2 binding, and Ago2 mediated
cleavage activity. Position 1 UNA modified siRNA
containing a 50-terminal phosphate exhibited a
partial restoration of siRNA silencing activity in
vivo. These data reveal the complexity of interpret-
ing the effects of chemical modification on siRNA
activity, and exemplify the importance of using
multiple biochemical, cell-based and in vivo assays
to rationally design chemically modified siRNA
destined for therapeutic use.
INTRODUCTION
RNA interference (RNAi) is a mechanism of posttrans-
lational gene silencing where double-stranded RNAs
(dsRNAs), such as a small interfering RNAs (siRNAs),
induce degradation of sequence speciﬁc homologous
mRNA (1). siRNAs are RNA duplexes of 19–21
nucleotides and are widely used for functional genetic or
cellular screens (2–4). RNAi-based therapy is also being
developed whereby a synthetic siRNA can be used to enter
the endogenous RNAi pathway and eliminate a gene of
interest, making it an attractive way to therapeutically
target genes outside of the small molecule druggable
genome (5,6). In order for a siRNA to be eﬀective upon
entering the cell, the siRNA must become phosphorylated
on the 50-end by Clp1 kinase and be incorporated into
the endogenous RNA-induced silencing complex (RISC),
which consists of Ago2, Dicer, and TRBP (2,7–10).
During this assembly, one of the two strands of the
siRNA, known as the passenger strand, is cleaved,
whereby the other strand, referred to as the guide
strand, binds to the Argonaute protein, Ago2 (11–13).
The guide strand in RISC associates with the complemen-
tary mRNA strand, cleaves the mRNA, and thereby
regulates gene expression (14).
Phosphorylation of the 50-end of siRNA is one of the
ﬁrst steps required for it to function in RISC (15,16).
Recently, Clp1 was identiﬁed as a mammalian RNA
kinase and shown to be responsible for the 50-end
phosphorylation of siRNAs (7). Speciﬁcally, when cell
lysates were immunodepleted of Clp1, exogenous siRNA
lacking a 50-phosphate could no longer stimulate cleavage
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had attenuated silencing potency were found to have
increased potency after synthetically applying a 50-end
phosphate to their guide strand (17–20). These studies
emphasize the critical role of Clp1-mediated phosphoryla-
tion on the ability of a siRNA to function in the cell.
Identifying the parameters of Clp1 substrate speciﬁcity
such as positional base preference, nucleoside modiﬁca-
tion tolerance or siRNA length will be essential for
optimizing siRNAs as therapeutics. Similarly, understand-
ing the eﬃciency of phosphorylation of a siRNA and how
that relates to Ago2 binding and mRNA degradation will
also improve this optimization process.
Many of the chemical modiﬁcations that are currently
tolerated in siRNAs reside in the 20 position on the ribose
ring. 20-methoxy modiﬁcations at position 2 on the guide
strand can reduce oﬀ target eﬀects and, when on either the
passenger or guide strand, reduce immune responses
(21,22). Other modiﬁcations such as 20-ﬂuoro or
20-deoxy can increase potency, serum stability and/or
half life while reducing immunostimulatory responses
(23,24). 20-O,40-C-methylene bicyclonucleosides, also
known as locked nucleic acids (LNAs), increase structural
stability and prolong serum half life by having an addi-
tional linkage between the 20 and 40 carbons, forcing the
ribose sugar to maintain a C30-endo pucker which is found
in A-form helices such as RNA (25). However, many of
these modiﬁcations have not been evaluated for their
impact on 50-phosphorylation or on siRNA strand
loading into Ago2 when placed near the 50-end of the
guide strand. Understanding how modiﬁcations to a
siRNA can impact these steps will be important for the
rational design of chemically optimized siRNA
therapeutics.
20,30 Seco nucleosides, also known as unlocked nucleic
acids (UNA’s), are a class of modiﬁcations whereby
the ribose ring becomes acyclic by removing the bond
between the 20 and 30 carbon atoms (26–29) (Figure 1A).
This change in sugar structure increases the nucleic acid
analog ﬂexibility, and, when incorporated into duplexes,
can reduce duplex stability as observed by lower thermal
denaturation temperatures (26,28,30–32). Recently,
UNAs were incorporated into the guide strand of
siRNAs designed against GFP at positions 3, 6, 12
and 18 and found to have target speciﬁc mRNA
degradation (32).
Here, we evaluate siRNA duplexes that were individu-
ally modiﬁed at every position in the guide strand with
UNAs. We found that modiﬁed positions 1–3, 9–12, 14
and 16 had decreased siRNA-mediated mRNA degrada-
tion in cells when compared to an unmodiﬁed siRNA.
UNA modiﬁcations at positions 1, 2, and 3 of the guide
strand were particularly detrimental to target mRNA deg-
radation. UNA modiﬁed siRNAs at position 1 or 2 were
also unable to be phosphorylated by Clp1 kinase,
exhibited decreased binding to Ago2 and impaired Ago2
cleavage of the mRNA target. Cell based mRNA degra-
dation and Ago2 binding activity of the UNA modiﬁed
siRNA at position 1 were successfully recovered by the
chemical addition of a 50-phosphate on the UNA
modiﬁed siRNA. When tested in mice, the 50-terminal
phosphate was also able to recover the activity of the
position 1 UNA modiﬁed siRNA.
MATERIALS AND METHODS
Oligo synthesis and sequence
All UNA containing oligos were synthesized at RiboTask
(Denmark). The oligo is derived from the ApoB gene at
positions 10162–10182 (50-UUCAGUGUUGAUGACA
CUUG-30 guide strand) with dTdT overhangs on the
30-ends of both the guide and passenger strands. Negative
control siRNA for the in vitro studies is (50-GUAUGACC
GACUACGCGUA-30-passenger strand).
Transfection and qPCR
Hepa1-6 cells were cultured in Dulbecco’s Modiﬁed Eagle
Medium (Mediatech Cellgro) containing 10% serum. Cells
were plated in a 96-well plate (3500cells/well) and were
transfected 24h after plating in Opti-MEM I Reduced
Serum Media (Gibco) and Lipofectamine RNAiMax
reagent (Invitrogen) for a ﬁnal concentration of 10nM
siRNA for the initial screening. For IC50 curves the
ﬁnal concentration ranged from 0.15pM to 160nM
along a 12-point titration curve. Approximately 24h
after transfection, cells were washed with phosphate-
buﬀered saline and lysed in Cells-to-CT Lysis Buﬀer
(Ambion) with rDNase I (RNase-Free) added. Stop
Solution (Ambion) was used to halt the reaction.
RT–PCR was performed using 7ml of cell lysate in 2X
RT Buﬀer with 20X RT Enzyme Mix (Ambion) added.
Conditions were as follows: 37 C for 60min and 95 C
for 5min. ApoB mRNA levels were detected by quantita-
tive PCR with ApoB-speciﬁc probes from Applied
Biosystems. All cDNA samples were added to a 10ml
reaction volume with the following cycling conditions:
2min at 50 C, 10min at 95 C, followed by 40cycles
of 15s at 95 C and 1min at 60 C. qPCR was assayed
using an ABI Prism 7900 sequence detector using 2x
Taqman Gene Expression Master Mix (Applied
Biosystems). GAPDH mRNA levels were used for data
normalization.
Melting temperature determination
Melting temperature (Tm) of siRNA duplexes was
measured using SYBR Green I (Invitrogen) and a 7500
Real-time PCR system with SDS software version 2.0.1
(Applied Biosystems). A 25ml reaction containing 5mM
siRNA, 5X SYBR Green stain and 50% PBS was run
using the 7500 instrument. The siRNA-SYBR mixture
was denatured at 99.9 C for 30s then subjected to a
10% ramp to 30 C for 8min. Samples were then heated
in 0.4 C steps with 30s holds from 30 C to a ﬁnal tem-
perature of 99.9 C. The SDS software performed the
melting curve analysis and Tm.
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HA-FLAG-hAgo2 was over-expressed in the Flp-In
T-Rex 293 cell line from Invitrogen. Cells were grown as
speciﬁed by the manufacturer. Protein expression was
induced for 24h with 1mg/ml tetracycline. An equivalent
amount of cells were grown similarly but without induc-
tion of protein expression. After 24h of protein expres-
sion, the media was aspirated and the cells were incubated
with lysis buﬀer consisting of 50mM KCl, 20mM HEPES
pH 7.5, 0.5mM Tris(2-carboxyethyl)phosphine (TCEP),
0.05% NP-40 and 1X protease inhibitor cocktail (Sigma-
Aldrich), for 30min at room temperature with gentle agi-
tation. Lysate was pooled and spun for 15min at 25000g.
The supernatant was immediately ﬂash frozen on dry ice
and stored at  80 C until needed. 10ml of 0.1mM siRNA
was added to 130ml of thawed cell lysate (2mg/ml) with
1.5ml of RNase inhibitor (Applied Biosystems). Samples
were incubated at 37 C for 4h. A total of 100ml of the
siRNA/cell lysate was transferred to an Anti-FLAG High
Sensitivity, M2 coated 96-well plate from Sigma-Aldrich.
The plate was incubated overnight with gentle agitation at
4 C. The next day the wells are washed with Tris-buﬀered
saline (TBS) and the siRNA eluted with 30ml of Cells-to-
Ct lysis buﬀer. The resulting siRNA was quantiﬁed by
Taqman PCR. The amount bound was calculated as the
Ct resulting from the experimental sample subtracted
from that of the negative control.
Ago2 cleavage
A total of 0.4mlo f1 0mM single strand siRNA was added
to a reaction containing 1.5mM puriﬁed hAgo2, 1X
cleavage buﬀer (20mM HEPES pH 7.5, 60mM NaCl
and 5mM MgCl2) and 20U of RNase inhibitor
(Ambion) in a ﬁnal volume of 20ml. The reaction was
incubated at 37 C for 30min. The target mRNA (Cy3-A
UUUCUCCUUUAAAUCAAGUGUCAUCACACUG
AAUACCAAUGCUGAACUU) was heated to 90 C for
1min then quick cooled on ice for three minutes in order
to eliminate any secondary structure. A 0.6ml of the
prepared target was added to the reaction after the
30min incubation and allowed to incubate at 37 C for
an additional 90min. The reaction was quenched with
20ml of cleavage loading dye (40mM EDTA, 0.2% SDS,
2mg/ml ProteinaseK and 1.78X TBE–urea sample buﬀer
(Invitrogen). The samples were then heated to 90 C for
90s and quickly cooled on iced to eliminate any secondary
structure. 20ml of each sample was loaded onto a 10-well,
15% TBE-urea gel (Invitrogen) and run at 180V for  1h.
The gel was rinsed in water and visualized on a Typhoon
8600 (GE Healthcare) with the Cy3 ﬂuorescence settings.
The bands were quantitated using ImageQuant software
and the graph expresses the percent cleavage of the total.
Clp1 puriﬁcation
The glutathione S-transferase (GST) tagged Clp1 (NM_
006831) fusion plasmid was generated by recombining full
length Clp1 into pDEST15 (Invitrogen), which was then
transformed into the Rossetta strain of Escherichia coli.
(Novagen) following the manufacturers instructions.
A modiﬁed procedure was used to induce the production
of the GST-Clp1 fusion protein (7). In brief, 500ml of
plasmid transformed E. coli in Luria broth containing
ampicillin (100mg/ml) and chloramphenicol (34mg/ml)
were induced with 0.4mM isopropyl b-D-thiogalactosidase
(IPTG) at 37 C for 2h. The bacteria induced to express
Clp1 were then collected by centrifugation at 10000r.p.m.
for 20min at 4 C.
The cell pellet was resuspended in 35ml of extraction
buﬀer [PBS at pH 7.4, containing 137mM NaCl, 27mM
KCl, 5mM MgCl2, 2.5mM DDT, 0.1mM 4-(2-
Aminoethyl) benzenesulfonyl ﬂuoride hydrochloride
(AEBSF), and 0.1% Triton X-100]. The cell suspension
was kept on ice and disrupted using the Sonic
Dismembrator (Fisher, model 500) by 6 consecutive 15-s
pulses with 1min pause. The cell lysate was centrifuged at
4 C for 20min at 12000r.p.m. and ﬁltered through
0.22mm ﬁlter. Aﬃnity puriﬁcation of Clp1 was per-
formed by chromatograph using GSTrap column on
AKTApuriﬁer system (GE) following the manufacturers
instructions with some modiﬁcation. Brieﬂy, a GSTrap
5ml column containing Glutathione-Sepharose Fast
Flow beads were equilibrated with 25ml of binding
buﬀer (extraction buﬀer without Triton X-100). The
35ml of ﬁltered cell lysate was loaded on a column
followed by washing with 25ml binding buﬀer. The
column was then eluted with 50mM Tris–HCl (pH 8.5)
buﬀer containing 20mM reduced glutathione, 100mM
NaCl, 5mM MgCl2, 0.1mM AEBSF and 2.5mM DTT.
Fractions containing Clp1 were pooled and concentra-
ted using 10KDa Centriprep centrifugal ﬁlter units
(Milipore). The concentrated protein was then exchanged
into kinase assay buﬀer (50mM Tris–HCl, pH 8.0 con-
taining 50mM KCl, 5mM MgCl2, 5mM DTT). GST-
Clp1 recombinant protein was analyzed by SDS-PAGE
gel. The identity of Clp1 was further conﬁrmed by gel
band protein ID on a Mass Spectrometer (Proteomics).
Protein sample concentration was determined by UV on
a NanoDrop-8000.
Clp1 assay
The siRNA-kinase activity assay was performed in 40mlo f
50mM Tris–HCl (pH 8.0) reaction mix, containing 10mg
of recombinant GST–Clp1, 50mM KCl, 5mM MgCl2,
5mM DTT, 1mM ATP, 0.2mM GTP and 1mM
siRNA, followed by incubation at 30 C for 1h. The
reaction was stopped by heating at 95 C for 5min. The
samples were then run directly on the mass spectrometer.
The percent phosphorylation was derived from the ratio
of phosphorylated to non-phosphorylated of the passen-
ger or guide oligonucleotide strand.
Mass spectrometry
All samples were run on a LC/MS system comprised of an
Applied Biosystems MDS Sciex API 4000 mass spectrom-
eter (Concord, Ontario, Canada) equipped with a Turbo
Ion Spray source and operating in the negative-ion
mode, two Shimadzu LC-20AD UFLC pumps
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autosampler (Carrboro, NC, USA) and a column heater
(Phenomenex, Tustin, CA, USA) operated at 70 C. Data
acquisition was performed with ABI/Sciex Analyst
software, version 1.5 and zero-charge state molecular
weights were determined by deconvolution using the
BioAnalyst software module. Ion-pair reversed phase
HPLC chromatographic separations were performed on
an XBridge OST C18 column (Waters, Milford, MA,
USA) 50mm 2.1mm, 2.5mm particle size at a ﬂow rate
of 200ml/min. Mobile phase A consisted of 1.7mM TEA
and 100mM HFIP (pH 7.5) in water, and mobile phase B
was methanol. A 20ml injection of each sample was loaded
onto the column and separated using the following elution
gradient: 3% B for 1min, 3% to 25% B over 3min, 95% B
for 1min followed by initial conditions for 2min for
column re-equilibration.
Modeling methodology
The 3.0-A ˚ structure of Argonaute from Thermus
thermophilus with bound DNA guide strand and RNA
passenger strand (PDB code 3F73) was aligned with the
human Ago2 sequence (GenBank accession number
NP_036286.2). Alignment was performed with MOE
software (Chemical Computing Group, Montreal,
Canada) and modiﬁed manually on observed and pre-
dicted secondary structure. A homology model was built
using MOE, with the duplex oligonucleotides present
during model construction. The structure of the human
PIWI domain (1SI3) was grafted onto the model by
aligning the linking residues Ile346-Val347 and Pro229-
Val230, excising the model PIWI domain, and attaching
the PIWI domain from 1SI3. The crude chimeric structure
was cleaned up by rebuilding a full-length Ago2 homology
model using the chimera as template. Next, the DNA
guide strand was converted into RNA, and the complex
was minimized with the protein heavy atoms ﬁxed, the
oligonucleotide heavy atoms constrained with a ﬂat-
bottomed potential of 0.5A width, and all hydrogen
atoms unrestrained.
50RACE
50-RACE was performed using a GeneRacer Kit
(Invitrogen). Total RNA was obtained from livers of
mice injected with 6mg/kg siRNA and sacriﬁced at 24h.
GeneRacer RNA Oligo was ligated to the 50-ends of
3–5mg of total RNA. The RNA was then precipitated
and reverse transcribed into cDNA using a gene speciﬁc
primer, 50-CTTGTGATCAATGCCTCCTGTTGC-30,
according to the GeneRacer Kit protocol. Two microliters
of cDNA was used for PCR with GoTaq Colorless
Master Mix (Promega), 1ml of the gene-speciﬁc primer,
and 3ml of GeneRacer 50 Primer. The following cycling
parameters were used: 2min at 95 C, 35cycles of 30s at
95 C, 1min at 55 C, 1min at 72 C, and a ﬁnal 7min
at 72 C. A second nested PCR was performed to aid in
the identifying of real RACE products. 2ml of the pervious
PCR reaction was used with GoTaq Colorless Master
Mix (Promega), 1ml of a second gene-speciﬁc primer,
50-GAGAGACAGCTGTGGCTAGTTTCAAT-30, and
1ml of GeneRacer 50 Nested Primer. Cycling parameters
were kept the same but only 25cycles were performed.
Samples were run on a 3% agarose gel with ethidium
bromide and imaged.
siRNA formulation
Lipid nanoparticles (LNPs) were made using the
cationic lipid CLinDMA (2-{4-[(3b)-cholest-5-en-
3-yloxy]-butoxy}-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,
12-dien-1-yloxy]propan-1-amine), cholesterol, and
PEG-DMG (monomethoxy(polyethyleneglycol)-1,2-
dimyristoylglycerol) in 50.3:44.3:5.4 molar ratio as
previously described (33). Brieﬂy, siRNAs were incorpo-
rated in the LNPs with high encapsulation eﬃciency by
mixing siRNA in buﬀer into an ethanolic solution of the
lipid mixture, followed by a stepwise diaﬁltration process.
Cholesterol was purchased from Northern Lipids, PEG-
DMG was purchased from NOF Corporation and
CLinDMA was synthesized by Merck and Co. The
encapsulation eﬃciency was determined using a SYBR
Gold ﬂuorescence assay and the particle size
measurements were performed using a Wyatt DynaPro
plate reader. The siRNA and lipid concentrations in the
LNP were quantiﬁed by a HPLC using a PDA detector.
In vivo
C57BL/6 male mice 20–23g were purchased from Taconic
Farms, Inc. After receiving, the mice rested for a week,
divided in groups of eight and injected intravenously with
200ml containing 6mg/kg siRNA formulated in a lipid
nanoparticle. Five mice per group were sacriﬁced at 24h
following siRNA injection. Livers were harvested and pro-
cessed to assess ApoB mRNA levels by qPCR as described
above.
RESULTS
Gene silencing activity of siRNAs containing UNAs in their
guide strand
A synthetic, double-stranded 21-mer corresponding to
positions 10162–10182 of the mRNA from the ApoB
gene was used. Positions 1–19 of both strands were
ribonucleotides, and the overhangs at positions 20
and 21 contained 20-deoxyribonucleotide thymidines
(Figure 1B). This unmodiﬁed siRNA was the template
for systematic evaluation of modiﬁed siRNAs containing
a single UNA at every position along the guide strand.
Mass spectrometry was used to conﬁrm that the
modiﬁed siRNA strands were intact and the most
adundant species (Supplementary Figure S1).
Functional ApoB siRNAs demonstrate target speciﬁc
mRNA degradation in cell based assays that can be
detected by quantitative PCR (qPCR). Hepa 1–6 cells
were transfected with either unmodiﬁed ApoB siRNA,
UNA-modiﬁed ApoB siRNA, or negative control
siRNA. Negative control siRNA did not induce ApoB
mRNA degradation. Unmodiﬁed siRNA resulted in deg-
radation of 92% of the total ApoB mRNA (Figure 1C).
For UNA modiﬁed siRNA, mRNA degradation activity
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the guide strand. UNA substitutions at position 1 or 2
did not exhibit any mRNA degradation activity. UNA
substitutions at position 3 exhibited only 42% of activity
as compared to unmodiﬁed siRNA. UNA substitutions at
positions 4–8 had similar activity to unmodiﬁed siRNA,
ranging from 77% to 92%. Substitutions at positions 13,
15, 17–19 or on the overhang positions 20 and 21 had
activity similar to unmodiﬁed siRNA (79–88%). UNA
substitutions at positions 9–12, 14 or 16 had attenuated
mRNA degradation and were signiﬁcantly diﬀerent from
unmodiﬁed (paired t-test, P<0.001), with values ranging
from  25% to 62% compared to the unmodiﬁed siRNA,
which was 92%. This is similar to a previously published
result where UNA modiﬁcations closer to the 50-end
(position 3) had reduced silencing activity and
modiﬁcations farther away from the 50-end at positions
6 and 18 had similar activity to unmodiﬁed (32).
Dose response analysis was conducted for each UNA
modiﬁed siRNA (Table 1). An unmodiﬁed ribonucleotide
containing siRNA had an IC50 of 0.123 nanomolar
(nM). For UNA modiﬁcations at positions 4–8, which
have similar mRNA degradation activity compared to
the unmodiﬁed siRNA, the IC50s were also similar.
While UNA modiﬁcations at positions 17–19 showed
mRNA degradation at 10nM similar to unmodiﬁed
siRNA, the IC50s were 10-fold higher (1.29, 1.02 and
1.20nM, respectively). The IC50s were also increased for
UNA modiﬁcations at positions 3, 9, and 12–14, which
also showed attenuated mRNA activity.
Clp1 siRNA kinase cannot phosphorylate siRNAs with
UNAs at position 1 or 2
Human Clp1 was expressed and puriﬁed from E. coli and
kinase activity assays were performed using duplexed,
unmodiﬁed siRNA. Mass spectrometry was used in
order to detect phosphorylation of both the passenger
and guide strands of the siRNA. Polynucleotide kinase
(PNK), a nucleotide kinase found in bacteria, was used
as a positive control to conﬁrm the integrity of the
siRNAs (Figure 2). PNK was able to phosphorylate
both RNA and DNA and work in a variety of buﬀer
conditions. Both strands of the unmodiﬁed siRNA were
completely phosphorylated by Clp1 following a 1h
Figure 1. UNAs at position 1, 2 and 3 of the guide strand impair mRNA degradation. (A) Structure of the nucleotides used for oligonucleotide
synthesis. (B) ApoB siRNA sequence used in this study. (C) Percent mRNA degradation of ApoB mRNA as determined by qPCR. Unmodiﬁed refers
to the ApoB siRNA sequence containing only ribonucleotides and dTdT overhangs. The negative control is a scrambled siRNA sequence. Individual
UNAs were substituted at the indicated position on the guide strand of the duplex. A paired t-test was conducted to evaluate UNA modiﬁcations to
the unmodiﬁed control. The asterisk indicates a signiﬁcant change in mRNA degradation from unmodiﬁed siRNA (P<0.001).
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modiﬁed siRNA containing UNAs at positions 1, 2 or 3 of
the guide strand (UNA1, UNA2, UNA3) were incubated
with Clp1. All passenger strands, which contain ribo-
nucleotides and no UNA modiﬁcations, were phos-
phorylated to completion. However, guide oligos UNA1
and UNA2 failed to be phosphorylated by Clp1. In
contrast, UNA3 was phosphorylated to completion by
Clp1. Interestingly, PNK was also not able to phos-
phorylate UNA1 above 20% after 1 h of incubation, but
was able to phosphorylate UNA2 and UNA3 to comple-
tion. Mass spectrometry of UNA1 conﬁrmed its integrity
(Supplementary Figure 1). These data suggest that Clp1
fails to recognize position 1 or 2 UNA-modiﬁed siRNAs
as nucleic acid substrates for 50-terminal phosphorylation.
50-terminal phosphorylation restores gene silencing when
the UNA is at position 1 but not at positions 2 or 3
Synthetic 50-terminal phosphorylation has been shown
to recover the mRNA degradation activity of siRNAs
(17–20,34). Since UNA1 and UNA2 are unable to be
phosphorylated on the 50-terminus by Clp1, we asked
whether these siRNAs could recover their ability to
induce degradation of target mRNA when prepared in a
phosphorylated form (7).
UNA1, 2 and 3 with a 50-terminal phosphate on the
guide strand were synthesized (UNA1P, UNA2P and
UNA3P, respectively). UNA1P had nearly full recovery
of mRNA degradation activity, with 85% mRNA degra-
dation, compared to its unmodiﬁed counterpart. UNA1
had no detectable target mRNA degradation when
Table 1. IC50s and melting temperatures of UNA modiﬁed siRNAs
siRNA Guide sequence (50!30) IC50(nM) Tm(  C) Tm(  C)
unmodiﬁed UUCAGUGUGAUGACACUUGdTdT 0.123±0.023 67.4
UNA1 unaUUCAGUGUGAUGACACUUGdTdT ND 66.4  1.0
UNA2 UunaUCAGUGUGAUGACACUUGdTdT ND 65.0  2.4
UNA3 UUunaCAGUGUGAUGACACUUGdTdT 3.83±2.28 63.0  4.4
UNA4 UUCunaAGUGUGAUGACACUUGdTdT 0.13±0.08 61.2  6.2
UNA5 UUCAunaGUGUGAUGACACUUGdTdT 0.21±0.05 58.2  9.1
UNA6 UUCAGunaUGUGAUGACACUUGdTdT 0.23±0.17 58.2  9.1
UNA7 UUCAGUunaGUGAUGACACUUGdTdT 0.39±0.12 58.8  8.6
UNA8 UUCAGUGunaUGAUGACACUUGdTdT 0.15±0.06 58.2  9.1
UNA9 UUCAGUGUunaGAUGACACUUGdTdT 2.31±0.73 60.4  7.0
UNA10 UUCAGUGUGunaAUGACACUUGdTdT ND 59.2  8.2
UNA11 UUCAGUGUGAunaUGACACUUGdTdT ND 59.8  7.6
UNA12 UUCAGUGUGAUunaGACACUUGdTdT 6.78±5.21 61.0  6.4
UNA13 UUCAGUGUGAUGunaACACUUGdTdT 2.17±0.46 59.8  7.6
UNA14 UUCAGUGUGAUGAunaCACUUGdTdT 3.09±0.85 56.8  10.5
UNA15 UUCAGUGUGAUGACunaACUUGdTdT 0.76±0.17 60.4  7.0
UNA16 UUCAGUGUGAUGACAunaCUUGdTdT ND 61  6.4
UNA17 UUCAGUGUGAUGACACunaUUGdTdT 1.29±0.28 64  3.4
UNA18 UUCAGUGUGAUGACACUunaUGdTdT 1.02±0.24 65  2.4
UNA19 UUCAGUGUGAUGACACUUunaGdTdT 1.20±0.74 64.8  2.6
UNA20,21 UUCAGUGUGAUGACACUUGunaUunaU 0.56±0.20 65.6  1.8
UNA, unlocked nucleic acid; ACGU, RNA; dTdT, deoxynucleotide overhang; Tm, diﬀerence between test and unmodiﬁed siRNA Tm; ND, could
not be determined.
Figure 2. Clp1 kinase failed to phosphorylate the 50-termini of siRNAs containing UNAs at position 1 or 2. (A) PNK was used as a control kinase
to evaluate phosphorylation of the siRNAs and to ensure the integrity of the synthesized siRNAs. siRNAs were incubated with PNK and samples
were run on the mass spectrometer as described in Materials and Methods section. Mass spectrometric analysis of the siRNAs indicated that the
siRNAs were intact. (B) Clp1 siRNA kinase assay was performed to evaluate the role of Clp1 in phosphorylation of UNA modiﬁed siRNA as
described in (A). Unmodiﬁed refers to the ApoB siRNA sequence containing only ribonucleotides and dTdT overhangs.
Nucleic AcidsResearch, 2010, Vol.38,No. 2 665administered at 10nM (Figure 3A). A dose–response
evaluation of UNA1P showed an IC50 of 0.26nM,
which is slightly less potent than the unmodiﬁed
siRNA (Table 2). UNA2P had no improvement in
mRNA degradation when compared to UNA2.
UNA3P also showed no improvement in mRNA degra-
dation. Unmodiﬁed siRNA with a 50-terminal phosphate
on the guide strand exhibited no change in mRNA deg-
radation consistent with previous results that siRNAs are
phosphorylated in cells (16). These data suggest that the
Figure 3. Chemical phosphorylation of siRNAs containing UNAs at position 1, but not position 2 or 3, restores biological activity in cell based
assays. (A)5 0-terminal phosphorylation of the guide strand restores activity when UNAs are at position 1. Unmodiﬁed refers to the ApoB sequence
containing only ribonucleotides and dTdT overhangs. The negative control is a scrambled sequence. Individual UNAs are placed at the indicated
position on the guide strand. Oligonucleotides with a 50-terminal hydroxyl group on the guide strand are shown in black and oligonucleotides with
a5 0-terminal phosphate on the guide strand are shown in white (all passenger strands contained a 50-terminal hydroxyl group). (B) Binding
of oligonucleotides to epitope-tagged Ago2 in cell lysates. Ago2 binding studies were performed as described in Materials and Methods section.
The percent of the UNA modiﬁed oligonucleotides bound to Ago2 was normalized to unmodiﬁed siRNA. The negative control refers to a sequence
that is mismatched to the stem loop PCR primers. (C) Cleavage by puriﬁed Ago2 of a Cy3 target oligo that mimics the cellular mRNA target.
The gel is on the right and quantiﬁcation of the cleavage is on the left. Ago2 cleavage studies were performed as described in ‘Materials and
Methods’ section.
Table 2. IC50 and melting temperature of UNA modiﬁed siRNAs with a 50-terminal phosphate on the guide strand
siRNA Guide sequence (50!30) IC50(nM) Tm(  C) Tm(  C)
unmodiﬁed UUCAGUGUGAUGACACUUGdTdT 0.123±0.023 67.4 –
UNA1 unaUUCAGUGUGAUGACACUUGdTdT ND 66.4  1.0
UNA1P P-unaUUCAGUGUGAUGACACUUGdTdT 0.26±0.18 66.6  0.8
UNA2 UunaUCAGUGUGAUGACACUUGdTdT ND 65.0  2.4
UNA2P P-UunaUCAGUGUGAUGACACUUGdTdT ND 66.4  1.0
UNA3 UUunaCAGUGUGAUGACACUUGdTdT 3.83±2.28 63.0  4.4
UNA3P P-UUunaCAGUGUGAUGACACUUGdTdT 4.95±2.39 63.4  4.0
P, phosphate; Tm, diﬀerence between test and unmodiﬁed siRNA Tm; ND, could not be determined.
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assays is predominantly due to its inability to be
phosphorylated by Clp1, whereas the loss of activity
for UNA2 and UNA3 substituted siRNA occurs for
other reasons.
The thermodynamic stability of siRNA does not change
with phosphorylation
Melting temperature experiments using SYBR Green
intercalation were conducted to assess the eﬀect of UNA
incorporation on the thermodynamic stability of the
siRNA duplexes. The SYBR Green melting temperature
assay has been validated as an acceptable way of measur-
ing oligo melting temperatures (35). We also validated
the assay using diﬀerential scanning calorimetry (DSC)
and UV melting temperature and saw a strong linear
correlation between SYBR Green and DSC methods
(R
2=0.9066, data not shown). All UNA modiﬁed
positions along the guide strand showed a decrease in
melting temperature, as compared to unmodiﬁed siRNA
(Table 1). These results are comparable to previous liter-
ature reports that evaluated the destabilizing eﬀect of
UNA substitutions in oligonucleotides (28,30,32). The
smallest changes in melting temperature were seen at the
50- and 30-positions including UNA1-3 and UNA18-19
where the largest were in the central region of the
siRNA. There were also small changes in melting temper-
ature for the overhang positions UNA20, 21. These results
for UNA20,21 are to be expected as the overhangs do not
make contact with any complementary bases and should
not aﬀect the overall thermodynamic stability of the
siRNA. Replacement of the 50-terminal hydroxyl with a
phosphate in the UNA modiﬁed oligonucleotides did not
have any impact on the melting temperature of UNA1P,
UNA2P or UNA3P indicating that the addition of a phos-
phate would not have a stabilizing eﬀect (Table 2).
Inhibition of Ago2 binding to the UNA1 siRNA can be
reversed by the addition of a 50-terminal phosphate
The crystal structure of T. thermophilus Ago2 revealed
that the 50-terminal phosphate and the position 1
nucleotide of the guide strand are not associated with
the complementary mRNA target strand (37,38). The
50-terminal phosphate does have strong interactions with
four invariant residues in the Mid domain of Ago2.
In contrast to position 1, the nucleotides in the seed
region of the guide strand (positions 2–8) are base
paired to the complementary strand in an A-form helix.
We investigated if the binding aﬃnity for Ago2 was
inﬂuenced by UNA modiﬁcations, and the impact of a
50-terminal phosphate on this aﬃnity. Duplexed siRNAs
containing various UNA substitutions, with or without a
50-terminal phosphate, were incubated in cell lysate con-
taining overexpressed and epitope tagged Ago2. The cell
lysate based Ago2 binding assay supports the introduction
of duplex siRNAs that interact with the RISC machinery
and allow guide strand loading into Ago2. Following
immunoprecipitation of Ago2, stem-loop qPCR was per-
formed to determine the amount of guide strand bound.
Stem loop PCR is a real-time Reverse Transcriptase
(RT)–PCR method in which a stem loop RT primer is
hybridized to a siRNA strand, then reverse transcribed.
The RT products are then quantiﬁed using conventional
Taqman PCR (36). All data were normalized to the
binding observed for the unmodiﬁed siRNA (Figure 3B).
An immunoblot blot was also performed to verify
equal amounts of Ago2 had been immunoprecipitated
(Supplementary Figure S2). When the unmodiﬁed
siRNA was synthetically phosphorylated on the
50-terminus, Ago2 binding increased slightly (an increase
of 20% compared to the unmodiﬁed siRNA). For UNA1
and UNA2, Ago2 binding was 40% and 21% of the
binding eﬃciency observed for unmodiﬁed siRNA, respec-
tively. When UNA1P was incubated with Ago2, the
binding increased to the same binding eﬃciency of
unmodiﬁed siRNA with a 50-phosphate. This represents
a 3-fold preference of UNA1P for Ago2 over UNA1.
Similarly, UNA2P bound with a 2-fold higher eﬃciency
than UNA2, although the total binding for UNA2P was
still only 40% of that seen with the unmodiﬁed siRNA
with a 50-phosphate. In contrast, UNA3 exhibited nearly
equal levels of binding to that seen for the unmodiﬁed
siRNA; thus, phosphorylation did not increase the
binding eﬃciency of UNA3. These results demonstrate
that position 1 UNA modiﬁcations have the unique
ability to have both mRNA degradation activity and
Ago2 binding rescued by a 50-end phosphate.
The cell-based mRNA degradation results (Figure 3A)
were also conﬁrmed with an Ago2 cleavage assay
(Figure 3C). This assay monitors cleavage of a Cy3
labeled oligo that is complementary to the siRNA guide
strand. The Cy3 target oligo is cleaved by Ago2 RNAse
activity when incubated with the siRNA guide strand and
Ago2. Neither the unphosphorylated all-ribose guide nor
the passenger strand gave any detectable cleavage of the
Cy3 target oligo. However, when the unmodiﬁed guide
strand siRNA was synthetically phosphorylated on the
50-terminus, 95% cleavage of the Cy3 target oligo was
detected. The same results were observed for UNA1P
and UNA3P, whereby the unphosphorylated siRNAs
gave no detectable cleavage of the Cy3 target oligo but
when a synthetic phosphate was applied to the 50-terminus
of the siRNA cleavage was observed of the Cy3 target
oligo. The Cy3 target oligo was cleaved less when
incubated with UNA3P than with UNA1P, having
only 20% compared to 33%, respectively. There was no
detectable cleavage of the Cy3 target oligo when incubated
with UNA2 or UNA2P. These results correlate with the
in vitro mRNA degradation and Ago2 binding results
(Figure 3A and B). They also demonstrate that 50-end
phosphorylation is necessary for cleavage of mRNA
target by these siRNAs and that these siRNAs proceed
through a RNAi-mediated mechanism to induce mRNA
degradation.
50-terminal phosphorylation restores gene silencing
in vivo for UNA1
In order to assess the if 50-terminal phosphorylation
of UNA1 also improves potency in vivo, ApoB siRNAs
corresponding to unmodiﬁed or UNA modiﬁed with or
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lipid nanoparticles and delivered by intravenous (IV) tail
injection into mice. PBS was delivered as a control. Lipid
nanoparticles localize to the liver, where ApoB is highly
expressed. Livers were harvested 24h after injection, and
ApoB mRNA levels were assessed by qPCR (Figure 4).
Mice treated with unmodiﬁed siRNA showed signiﬁcant
ApoB mRNA degradation compared to the PBS control,
with 76% mRNA degradation 24h after injection. For
UNA1, 16% mRNA degradation was observed after
24h and was not signiﬁcantly diﬀerent from the PBS
control (paired t-test, P<0.05). For UNA1P, 46% of
the ApoB transcript was degraded following IV
administration. The ability of UNA1P to silence ApoB
mRNA following injection was signiﬁcantly diﬀerent
from UNA1 although phosphorylation alone was not
able to rescue all the potency observed with the
unmodiﬁed siRNA (Figure 4). This decrease of in vivo
potency in UNA1P compared to the unmodiﬁed siRNA
is consistent with the IC50 data (Table 2), where UNA1P
had a two-fold decrease in IC50 value from the unmodiﬁed
siRNA.
50RACE was performed on the in vivo samples to dem-
onstrate that mRNA cleavage and degradation occurred
through an Ago2 speciﬁc mechanism. 5’RACE involves
ligation of a tag to the 50-end of the cleavage site
Figure 4. UNAs demonstrate in vivo activity at 24h post-IV injection. (A) Unmodiﬁed siRNA, siRNA with an UNA at position 1 (UNA1),
and siRNA containing a 50-terminal phosphate with UNA at position 1 (UNA1P) were formulated into lipid nanoparticles and injected in mice
at 6mg/kg. The livers were harvested and ApoB mRNA levels were evaluated by qPCR 24h after injection (student’s t-test, P<0.0001). Bars
represent the mean and standard deviation of ﬁve mice per group. (B) UNA1 and UNA1P function via an Ago2 mechanism. 50RACE was used to
detect the ApoB mRNA cleavage site. Mouse liver RNA samples were evaluated for each sample group. 50RACE products are 150bp. The precise
Ago2-mediate cleavage site on ApoB was mapped by sequencing and is designated by an arrow. The yellow box indicates the 50-RACE linker
sequence.
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ligation-speciﬁc primer and a gene speciﬁc downstream
primer. If Ago2-mediated cleavage occurs, the ampliﬁca-
tion of this region would be 150bp. If no cleavage occurs
there would not be an ampliﬁcation product since the
length of the ApoB from its endogenous 50 terminus to
the cleavage site would be 10162bp and the PCR exten-
sion time is optimized for 150bp. 50-RACE does not
provide quantiﬁcation of the amount of cleavage that
occurs, only that cleavage occurred via an Ago2 mecha-
nism. 50RACE was performed on the samples and run on
an agarose gel. Bands corresponding to 150bp appear for
the unmodiﬁed all ribose siRNA and UNA1P siRNA. No
band was detected for UNA1 which may be due to the low
level of cleavage that could not be detected by 50RACE.
These bands were sequenced and cleavage of the mRNA
corresponded to between position 10 and 11 of the guide
strand of the siRNA, thus conﬁrming UNA1P mRNA
degradation in vivo proceeds through an Ago2-mediated
mechanism.
DISCUSSION
In this study, we systematically evaluated UNA sub-
stitutions throughout the guide strand of a siRNA target-
ing the ApoB transcript. Substitution of an UNA at
position 1 or 2 of the siRNA had a detrimental eﬀect on
mRNA degradation, Clp1 phosphorylation, Ago2
binding, and Ago2 cleavage. Chemical addition of a
50-terminal phosphate allowed for the recovery of
mRNA degradation activity and Ago2 binding and
cleavage to UNA1, but not UNA2. 50-phosphorylation
of UNA1 also rescued siRNA silencing activity in vivo
and was consistent with the determined IC50s for the
unmodiﬁed siRNA and UNA1P. These data indicate the
importance of conducting dose response analysis as well as
maximal mRNA degradation measurements in order to
fully characterize the impact of a chemical modiﬁcation
on the activity of a siRNA.
Clp1 is the kinase responsible for exogenous siRNA
phosphorylation. The ideal parameters under which
Clp1 operates remain to be deﬁned (7). In this study,
mass spectrometry was used to identify phosphorylation
of the passenger and guide strand by Clp1. These data
suggest for the ﬁrst time that Clp1 may recognize
chemical features of position 1 and 2 of the siRNA in
order to phosphorylate the 50-terminus. If either of these
positions are modiﬁed with a UNA, Clp1 can no longer
phosphorylate the 50-terminus. This failure to be
phosphorylated is the most likely reason UNA1 has
decreased silencing activity since synthetic addition of a
50-phosphate rescues mRNA degradation activity in cells
and in mice. The loss of silencing activity for UNA2 and
UNA3 is more likely due to the structural complexity
induced by the UNA modiﬁcations rather than the
lack of phosphorylation since chemical addition of a
50-terminal phosphate to these oligonucleotides does not
rescue this activity.
The molecular events responsible for 50-phosphate
recognition during RISC assembly remain to be deﬁned.
Position 1 is unique in that it does not seem to have a
role in mRNA target identiﬁcation or in maintaining the
structural stability of the siRNA, but instead has a role
in RISC loading and guidance of the rest of the siRNA
into Ago2 (9,37). In the Ago2 crystal structure, the
50–phosphorylated nucleotide at position 1 ﬁts into a
basic pocket with the 50 base stacking on the aromatic
ring of an invariant tyrosine, further stabilizing this
binding (38,39). Interestingly, the UNA modiﬁcation
at position 1 does not impair Ago2 binding when a
50-terminal phosphate is present, indicating that it is
the lack of phosphorylation, not the modiﬁcation that
prevents eﬃcient binding. In the Ago2 crystal structure
at position 1 there is a ﬂexible protein loop that should
accommodate additional movements that could be caused
by the UNA modiﬁcations (Supplementary Figure S3).
In contrast, the opposite is true for UNAs in positions 2
and 3, where the contacts involve the sugar phosphate
backbone of the nucleotides and the bases are positioned
next to each other to direct bonding to the target mRNA.
For position 2 the base of the nucleoside would be
between the base of position 3, and the helix of Ago2
between residues 556 and 571. This makes the position 2
base less able to accommodate the movements in the sugar
and the base that could be introduced by the UNA. The
base at position 3 would be between position 2 and 4 and
suﬀer from the same steric hindrances. The lack of the
20C-30C bond in the ribose sugar increases the structural
instability, diminishes the strength or number of contacts
of the backbone with Ago2 and the target mRNA at
positions 2 and 3, and leads to a lack of degradation of
target mRNAs due to incorrect positioning of the position
2 or 3 UNA modiﬁed siRNA. In addition, UNAs at
positions 1–2 also cause duplex instability, as reﬂected in
the data obtained from thermal denaturation studies
(Table 1). This would translate into decreased stability
of the duplex formed between the UNA containing
guide strand with the mRNA and the decreased mRNA
degradation.
The UNA1P is less potent than the unmodiﬁed siRNA
in vitro and in vivo. One reason for this may be due to
50-terminal phosphate instability. If the 50-phosphate is
removed in the cytoplasm the UNA could not be
rephosphorylated by Clp1 since UNAs are not substrates
for Clp1 at position 1 (Figure 2). Another possibility could
be due to decreased Ago2 mediated cleavage by UNA1P
as compared to the unmodiﬁed siRNA. Both UNA1P and
the unmodiﬁed siRNA bind equally to Ago2. However,
less Ago2 mediated mRNA cleavage is observed
from UNA1P as compared to the unmodiﬁed siRNA.
The lack of activity seen from UNA1P would therefore be
driven by its inability to cleave its mRNA target with the
same eﬃciency as unmodiﬁed. Further pharmacokinetic
studies examining 50-terminal phosphate stability and
mRNA cleavage in vivo will elucidate the mechanism for
the UNA1 decrease in potency.
Chemical modiﬁcations of siRNAs are critical for
optimizing siRNA as human therapeutics. In this study,
we systematically evaluated UNA substitutions through-
out the guide strand of a siRNA targeting the ApoB tran-
script. Dose response analysis of the UNA substituted
Nucleic AcidsResearch, 2010, Vol.38,No. 2 669siRNAs in positions 2–8 showed that UNAs were
tolerated at positions 4-8 but were detrimental when
substituted at positions 1, 2 or 3 of the guide strand.
Furthermore, we demonstrate an UNA substitution at
position 1 or 2, but not position 3, blocked human Clp1
phosphorylation, subsequent Ago2 binding and Ago2
mediated target cleavage. Taken together these results
suggest that human Clp1 utilizes speciﬁc nucleic acid rec-
ognition elements at both positions 1 and 2 to allow
siRNA phosphorylation and RISC loading. Based on
these ﬁndings, UNA modiﬁcations, as well as other
novel nucleoside modiﬁcations that function similarly in
the guide strand with respect to Clp1 phosphorylation,
may be best suited for position 1 or 2 substitution of the
passenger strand to block phosphorylation and abrogate
RISC loading. Such a strategy would improve potency
due to lack of RISC loading of the passenger. Further
studies incorporating these novel nucleosides will help
identify the additional beneﬁcial properties that they can
confer to siRNAs.
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